Kama Capital Enhances Trader Engagement with Performance-Based Loyalty Program
A New Approach to Trader Rewards
Unlike conventional brokerage loyalty programs that often center on deposit-based incentives, Kama Capital's program is structured to offer traders tangible benefits at various stages of their trading journey.
'Our Loyalty Program is an extension of our mission—to provide traders with meaningful rewards that contribute to their long-term success,' said Razan Assaf, Deputy CEO of Kama Capital. 'We have developed a model that prioritizes traders by offering real benefits rather than promotional incentives.'
Program Highlights
The Kama Capital Loyalty Program offers multiple incentives, including:
Welcome Bonus ($10): Traders who complete KYC verification receive a starting bonus to begin trading.
First Deposit Bonus (10% up to $100): New traders can receive additional capital when funding their accounts.
Volume-Based Rewards: Traders earn rewards based on their trading activity.
Monthly Challenges: Additional incentives are available for top-performing traders who achieve key milestones in profitability and engagement.
Elena Kupriianova, Chief Marketing Officer at Kama Capital, emphasized the program's focus on long-term trader engagement. 'This initiative ensures that traders are recognized and rewarded for their continued activity in the market.'
Supporting Trader Growth
Kama Capital's approach aims to provide traders with incentives that align with their trading objectives. 'Loyalty programs should offer meaningful value rather than just encourage deposits,' said Basem Elhelaly, Customer Support Manager. 'Our goal is to create an environment where traders feel supported and in control of their growth.'By integrating structured rewards with trading performance, Kama Capital seeks to offer a program that enhances trader engagement while maintaining transparency and value.
About Kama CapitalKama Capital is a financial services provider specializing in trading solutions that cater to a diverse range of market participants. The company focuses on offering a flexible and transparent trading environment, providing tools and resources designed to support traders in navigating global financial markets. With a commitment to innovation and trader empowerment, Kama Capital aims to enhance the trading experience through technology-driven solutions and customer-centric initiatives.
For more information about the Kama Capital Loyalty Program, users can visit: Kama Capital Loyalty Program
Contact
Head of Digital & PartnershipsKarthik R. ArumugamKama Capital LLCk.arumugam@kama-capital.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/143b22ca-d8a5-4615-a36f-37a80337a722Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the control arm Improvement in PFS was achieved across virtually all subgroups, including those with poor prognostic factors A profound effect was observed in patients with PD-L1 negative tumors treated with Cylembio plus pembrolizumab, HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months for the control arm A trend towards improvement in overall survival (OS) was observed in patients treated with Cylembio plus pembrolizumab (OS not yet mature), HR=0.79 (CI 0.57-1.10) Cylembio plus pembrolizumab was well tolerated, with no new safety signals observed IO Biotech plans to meet with the FDA this fall to discuss the data and next steps for a potential regulatory submission Company to host conference call today at 8:30 a.m. ET to discuss these results NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted). The trial evaluated Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), vs. pembrolizumab alone as a first-line treatment in 407 patients with unresectable or metastatic (advanced) melanoma. In the study, Cylembio plus pembrolizumab demonstrated clinical improvement in progression free survival compared to pembrolizumab alone, but statistical significance was narrowly missed on the primary endpoint. 'In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio,' said Mai-Britt Zocca, PhD, president and chief executive officer of IO Biotech. 'The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data.' The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1. The early and sustained separation of PFS curves demonstrated an improvement with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056; threshold for significance p≤0.045]. Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet mature, a trend toward an improvement in overall survival was also observed [HR 0.79 (95% CI: 0.57-1.10)]; the company expects OS to mature over the next six to nine months. Improvement in PFS was achieved across virtually all subgroups, including those with poor prognostic factors, with a profound effect in patients with PD-L1 negative tumors treated with Cylembio plus pembrolizumab (n=67) compared to patients treated with pembrolizumab monotherapy (n=63), HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months, respectively. Additionally, in a post hoc analysis of patients enrolled in this study without prior anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS compared to patients treated with pembrolizumab monotherapy, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months, respectively. The combination was well tolerated, with no new safety signals observed. Injection site reactions, which were transient and resolved on treatment, were the most commonly reported adverse events in the combination arm, with 56% of patients receiving Cylembio plus pembrolizumab reporting an event. 'In this study, patients treated with Cylembio in combination with pembrolizumab have achieved the longest median PFS ever observed in a Phase 3 clinical study in advanced melanoma, and in the PD-L1 negative population, patients achieved a remarkable 16.6 months of median PFS, compared to 3.0 months in patients treated with pembrolizumab alone,' said Omid Hamid, MD, Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate. 'The significant benefit seen across patients with poor prognostic factors, including PD-L1 negative patients, cannot be overlooked. Given the notable safety profile and the strong clinical effect observed with Cylembio, as well as the unmet need in advanced melanoma patients, Cylembio, if approved, has the potential to become a new standard of care for patients with advanced melanoma.' 'These data show the potential of a therapeutic cancer vaccine in patients with metastatic melanoma,' said Jessica Hassel, MD, Professor at the Department of Dermatology and National Center for Tumor Diseases at the University Hospital Heidelberg, Germany, and lead enrolling investigator for the Phase 3 trial. 'We were thrilled to play such an important part in this study and to have had the ability to offer our patients an investigational therapy that potentially offers improvements in PFS while not adding significant systemic toxicity.' 'Delaying progression and improving survival is the ultimate treatment goal for patients and although overall survival is not yet mature, the trend we are seeing in OS with separation of the curves is encouraging, with a consistent PFS clinical improvement and OS trend favoring the combination arm across virtually all subgroups, with no new safety signals or significant additional systemic toxicity,' said Qasim Ahmad, MD, chief medical officer of IO Biotech. 'We are deeply grateful to the patients for their participation in this study, as well as to investigators and study coordinators whose dedication and collaboration brings us one step closer to delivering a new treatment option to patients in need.' 'Since reporting the positive outcome of our Phase 1/2 study (MM1636) in a similar patient population, we have been eagerly awaiting these results supporting the activity of Cylembio combined with an anti-PD-1 in patients with advanced melanoma,' said Inge Marie Svane, MD, PhD, Professor, Director of the National Center for Cancer Immune Therapy (CCIT) at the Copenhagen University Hospital, Herlev and Principal Investigator in the Phase 3 trial. 'These data provide evidence that a therapeutic cancer vaccine can improve progression free survival in patients with metastatic disease.' Based on these results, IO Biotech plans to meet with the United States (US) Food and Drug Administration (FDA) this fall to discuss the totality of data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma. Additionally, the company plans to present more detailed results from the IOB-013 study at an upcoming medical meeting. Conference Call and Webcast Information IO Biotech management will hold a conference call and webcast today at 8:30 a.m. ET to discuss these clinical data results. Participants can register for the live webcast here. The live webcast and replay will be available through IO Biotech's website here. About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 ( NCT05155254) was an open label, randomized Phase 3 pivotal clinical trial evaluating Cylembio® in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma. Enrollment in the trial was completed by December 2023 with a total of 407 patients enrolled from more than 100 centers across the United States, Europe, Australia, Turkey, Israel and South Africa. The primary endpoint of the study was progression free survival. Secondary endpoints include overall response rate, overall survival, durable objective response rate, complete response rate, duration of response, time to complete response, disease control rate, and incidence of adverse events and serious adverse events (safety and tolerability). Biomarkers in the blood and tumor tissue will also be assessed as exploratory endpoints. The company reported topline results from this trial in the third quarter of 2025. IO Biotech is sponsoring the Phase 3 trial and Merck is supplying pembrolizumab. About Cylembio® Cylembio® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the Phase 3 trial was completed rapidly by December 2023 with topline results from this trial reported in the third quarter of 2025. Enrollment in the two ongoing company-sponsored Phase 2 clinical trials is now complete. The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the US and Canada). About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit Follow us on our social media channels on LinkedIn and X (@IOBiotech). Forward-Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with the FDA, submission of a BLA, the launch of Cylembio, and statements regarding other current or future clinical trials, their progress, enrollment or results, or the company's financial position or cash runway, are based on IO Biotech's current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Contacts: InvestorsMaryann Cimino, Director of Investor RelationsIO Biotech, Inc.617-710-7305mci@ MediaJulie beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
Barrick Reports Share Repurchases and Declares Enhanced Q2 Dividend
All amounts expressed in US dollars TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) ('Barrick' or the 'Company') today announced the declaration of an enhanced dividend of $0.15 per share for the second quarter of 2025. The dividend is consistent with the Company's Performance Dividend Policy announced at the start of 2022. The Q2 2025 dividend will be paid on September 15, 2025 to shareholders of record at the close of business on August 29, 2025. In addition to the enhanced quarterly dividend, Barrick repurchased 13.50 million shares during Q2 under the share buyback program that was announced in February 2025. As of the end of Q2, Barrick has repurchased approximately 21.19 million shares under this year's program, or approximately 1.2% of Barrick's issued and outstanding shares at the time the program was announced, for net cash of $411 million, including $268 million paid during Q2. 'The combination of the performance dividend policy and share buyback program allow us to provide significant benefits to our shareholders,' said senior executive vice-president and chief financial officer Graham Shuttleworth. 'Along with our solid operating performance, strong cash flows and strategic initiatives, we continue to provide meaningful returns while maintaining a robust balance sheet.' About Barrick Mining Corporation Barrick is a leading global mining, exploration and development company. With one of the largest portfolios of world-class and long-life gold and copper assets in the industry — including six of the world's Tier One gold mines — Barrick's operations and projects span 18 countries and five continents. Barrick is also the largest gold producer in the United States. We create real, long-term value for all stakeholders through responsible mining, strong partnerships and a disciplined approach to growth. Barrick shares trade on the New York Stock Exchange under the symbol 'B' and on the Toronto Stock Exchange under the symbol 'ABX'. Enquiries Group investor and media relationsKathy du Plessis+44 20 7557 7738barrick@ Cautionary Statement on Forward-Looking Information Certain information contained or incorporated by reference in this press release, including any information as to our strategy, projects, plans, or future financial or operating performance, constitutes 'forward-looking statements'. All statements, other than statements of historical fact, are forward-looking statements. The words 'will', 'perform', 'maintain', 'growth' and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to Barrick's operating and financial performance, liquidity available to invest in growth projects, and the potential for Barrick to deliver enhanced dividends to shareholders under its Performance Dividend Policy. Forward-looking statements are necessarily based upon a number of estimates and assumptions including material estimates and assumptions related to the factors set forth below that, while considered reasonable by the Company as at the date of this press release in light of management's experience and perception of current conditions and expected developments, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements, and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: changes in national and local government legislation, taxation, controls or regulations and/ or changes in the administration of laws, policies and practices; expropriation or nationalization of property and political or economic developments in jurisdictions in which the Company or its affiliates do or may carry on business in the future; fluctuations in the spot and forward price of gold, copper, or certain other commodities (such as silver, diesel fuel, natural gas, and electricity); the speculative nature of mineral exploration and development; assumptions relating to the trading price of the Company's common shares; changes in mineral production performance, exploitation, and exploration successes; disruption of supply routes which may cause delays in construction and mining activities at Barrick's more remote properties; diminishing quantities or grades of reserves; increased costs, delays, suspensions and technical challenges associated with the construction of capital projects; operating or technical difficulties in connection with mining or development activities; failure to comply with environmental and health and safety laws and regulations; timing of receipt of, or failure to comply with, necessary permits and approvals; the impact of global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future cash flows; changes in U.S. trade, tariff and other controls on imports and exports, tax, immigration or other policies that may impact trade relations with foreign countries, result in retaliatory policies, lead to increased costs for raw materials and components, or impact Barrick's existing operations and material growth projects; the impact of inflation; fluctuations in the currency markets; lack of certainty with respect to foreign legal systems, corruption and other factors that are inconsistent with the rule of law; damage to the Company's reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Company's handling of environmental matters or dealings with community groups, whether true or not; the possibility that future exploration results will not be consistent with the Company's expectations; risks that exploration data may be incomplete and considerable additional work may be required to complete further evaluation, including but not limited to drilling, engineering and socioeconomic studies and investment; risk of loss due to acts of war, terrorism, sabotage and civil disturbances; risks associated with illegal and artisanal mining; risks associated with new diseases, epidemics and pandemics; litigation and legal and administrative proceedings; contests over title to properties, particularly title to undeveloped properties, or over access to water, power and other required infrastructure; business opportunities that may be presented to, or pursued by, the Company; risks associated with working with partners in jointly controlled assets; employee relations including loss of key employees; increased costs and physical risks, including extreme weather events and resource shortages, related to climate change; risks related to the failure of internal controls; risks related to the impairment of the Company's goodwill and assets; and availability and increased costs associated with mining inputs and labor. In addition, there are risks and hazards associated with the business of mineral exploration, development, and mining, including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins, flooding and gold bullion, copper cathode or gold or copper concentrate losses (and the risk of inadequate insurance, or inability to obtain insurance, to cover these risks). Many of these uncertainties and contingencies can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Readers are cautioned that forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements. Specific reference is made to the most recent Form 40-F/Annual Information Form on file with the SEC and Canadian provincial securities regulatory authorities for a more detailed discussion of some of the factors underlying forward-looking statements and the risks that may affect Barrick's ability to achieve the expectations set forth in the forward-looking statements contained in this press release. Barrick disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
CBD Pouches Market to Hit Valuation of US$ 535.62 Million By 2033
CBD pouches market is currently defined by a surge in consumer demand for convenient, smoke-free wellness products. Innovation in flavors and precise, moderate dosages are attracting a broader, health-conscious demographic, solidifying its mainstream appeal. Chicago, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The global CBD pouches market was valued at US$ 90.12 million in 2024 and is expected to reach US$ 535.62 million by 2033, growing at a CAGR of 21.9% during the forecast period 2025–2033. The market is maturing rapidly, driven by specific consumer preferences and strategic product positioning. The dominance of the 10-20 mg dosage illustrates a consumer base that is increasingly educated, seeking tangible wellness benefits without overwhelming effects. This segment has become the core of the CBD pouches market by successfully bridging the gap between cautious new users and experienced consumers. The preference for flavored options underscores the importance of the user experience; by removing the barrier of unpleasant taste, brands have made CBD consumption more accessible and enjoyable, integrating it into daily routines as a lifestyle product rather than a purely medicinal one. This is a key growth engine for the entire market. Download Sample Pages: The resilience of offline retail channels in the CBD pouches market speaks volumes about the consumer's need for trust and immediacy in this sector. In an industry still navigating complex regulations, the ability to interact with a product and a knowledgeable salesperson provides a level of assurance that online platforms struggle to match. Physical stores serve as crucial educational hubs, building consumer confidence and fostering loyalty through direct engagement. Looking ahead, the synergy between these dominant segments—a trusted, palatable product at an effective dose, available in a reliable retail environment—will continue to define the growth trajectory of the industry. Key Findings in CBD Pouches Market Market Forecast (2033) US$ 535.62 million CAGR 21.9% Largest Region (2024) North America (59%) By Content 10-20mg (52%) By Type Flavored (88%) By Distribution Offline (68%) Top Drivers Increasing consumer awareness of CBD's potential health and wellness benefits. Growing demand for smokeless and discreet alternatives to conventional tobacco. Progressive legalization of cannabis products, increasing accessibility and social acceptance. Top Trends Rising interest in microdosing and low-dose CBD product formulations. Enhanced focus on product transparency through third-party lab testing results. Innovation in formulations to include functional ingredients beyond just CBD. Top Challenges Navigating the complex and often inconsistent legal and regulatory landscape. Strict advertising and marketing restrictions imposed by major online platforms. High market competition and content saturation for key search terms. U.S. Hemp Production Forms a Robust Market Foundation The viability of the CBD pouches market is fundamentally tied to its agricultural backbone. In 2024, the United States saw 45,294 acres of industrial hemp planted in the open. Of this, a total of 32,694 acres were harvested. Data from 8,153 surveyed hemp producers reveals a highly specialized cultivation landscape. Floral hemp, the primary source for CBD, accounted for 20.8 million pounds produced from 11,827 harvested acres. This reflects a significant yield increase of 669 pounds per acre compared to the previous year, with an average yield of 1,757 pounds per acre. In parallel, production under protection (e.g., greenhouses) utilized 3.52 million square feet, yielding 356,000 clones and transplants, 49,420 pounds of floral hemp, and 2,364 pounds of seed hemp. Other segments included fiber hemp, with 60.4 million pounds produced from 18,855 acres at an average yield of 3,205 pounds per acre. Grain hemp production stood at 3.41 million pounds from 4,863 acres, while seed hemp production in the open yielded 697,000 pounds from 2,160 acres. Unpacking the Economic Realities of Raw Material Pricing The total value of U.S. hemp production in 2024 reached an impressive $445 million. This was comprised of $417 million from hemp grown in the open and $28.7 million from crops under protection. Floral hemp was the most valuable segment at $386 million, followed by seed hemp at $16.9 million, fiber hemp at $11.2 million, and grain hemp at $2.62 million. These values translate into specific wholesale costs that shape the final price within the CBD pouches market. In 2024, CBD biomass costs ranged from a low of $8.50 to a high of $230 per pound. Farmers often received $150 per pound for machine-trimmed outdoor CBD flower, while premium indoor-grown flower commanded an average of $600 per pound. For biomass with a 10% CBD content, the rate was $3.00 per pound. Looking ahead, Q2 2025 price projections per metric ton of hemp are $3,998 in the USA, $1,330 in China, $3,417 in Germany, and $3,210 in the Middle East, highlighting global cost differentials. Product Innovation and Composition Define Competitive Edges Product differentiation is a critical success factor in the competitive CBD pouches market. Market leader Cannadips exemplifies this trend with a standard tin containing 15 pouches, each with 10mg of water-dispersible CBD for a total of 150mg. Their 5x strength line significantly increases potency to 50mg of CBD per pouch, totaling 750mg per tin. Across these lines, the company offers a combined 8 flavors, including American Spice and Tropical Mango. Competitor Chill CBD Pouches offers products with a potency of 10-15mg per pouch. This innovation is happening within regulatory guardrails; for instance, French regulations in 2024 mandated a daily consumption limit of 50mg of CBD per person, a key constraint for product formulation in that region. The diversity of strength and flavor profiles underscores the industry's response to varied consumer demands. Corporate Strategy and Market Expansion Drive Brand Growth Strategic expansion is a dominant theme in the CBD pouches market as companies seek to establish a broader footprint. In a landmark move outside its home state, Cannadips announced in November 2024 its entry into the Arkansas market. This move expands its reach beyond the 6,000 stores where its hemp pouches are already available. Other cannabis-related companies are also expanding, with Aurora Cannabis acquiring MedReleaf Australia in February 2024 and Curaleaf acquiring Northern Green Canada in May 2024 to bolster international operations. New entrants are also making waves; Juana Dips, launched in 2024, already sold its cannabis pouches in 2 states (Colorado and Massachusetts) as of early 2025 and was in licensing talks with 13 companies in other states to rapidly scale its brand presence. Navigating the Complex and Shifting Global Regulatory Maze The regulatory environment remains a pivotal and fluid element influencing the CBD pouches market. In the U.S., the FDA Commissioner testified before a House committee on April 11, 2024, reaffirming the agency's position on needing a new regulatory pathway for CBD products. Progress is being made, as in June 2025, the FDA received 2 public comments supporting the addition of a "cannabinoid hemp product" category to its safety reporting system. In Europe, Switzerland introduced a new tobacco law in October 2024 that also governs industrial hemp flowers. Meanwhile, a February 2024 bill signed into law legalized medical cannabis in Ukraine, opening a new market. Conversely, Italy imposed significant restrictions on "cannabis light" in 2024 and, via a decree on June 27, 2024, classified CBD as a narcotic medicinal substance, creating substantial market hurdles. Clinical Research and Scientific Inquiry Bolster Consumer Trust Credibility and consumer trust are being built through rigorous scientific validation. A significant multicenter trial in India with 178 participants, with results reported in 2024, assessed an oral CBD solution for anxiety. Further research from a 2021 clinical trial involving 8 weeks of daily CBD use showed potential for enhancing natural killer cells. In 2025, a UCSD clinical trial studying CBD for early psychosis remains active, with plans to randomize approximately 120 patients. Demonstrating the ongoing effort to understand the substance, a study with 6 healthy adults characterized the urinary pharmacokinetic profile of 100-mg oral and vaporized CBD, with its proceedings published in October 2024. This growing body of clinical evidence is crucial for the long-term mainstream acceptance of the CBD pouches market. A Surge in Innovation and Intellectual Property Filings The future of the CBD pouches market is being written in its patent filings. A systematic review published in May 2025, which initially retrieved 99 patents filed between 2012 and 2024, ultimately included 15 relevant patents on cannabis drug delivery systems, highlighting the pace of innovation. Specific to the pouch format, a patent application for a "Cannabinoid pouch" was published on July 18, 2024. Another key filing, patent application WO2025116961A1 for cannabis compositions and oral products, is cited for 2025, indicating future product pipelines. These filings demonstrate a clear industry trend toward protecting novel formulations and delivery technologies, which will serve as a key competitive differentiator and barrier to entry in the coming years. Expanding Retail Footprints and Strategic Distribution Channels Accessibility is key to market growth, and distribution channels are widening significantly. In a pivotal move in 2024, pharmacies in France were authorized to sell CBD-based food supplements, opening a trusted and mainstream retail avenue. Trade shows remain a vital platform for brand visibility. Cannadips showcased its products at the 2024 InterTabac Trade Fair in Dortmund, Germany, from September 19-21. The company occupied booth number A29 in hall number 6, demonstrating a strategic investment in reaching European distributors and retailers. This expansion into both pharmaceutical and international trade channels is essential for moving CBD pouches from specialty items to everyday consumer goods, directly fueling growth in the CBD pouches market. Need a Customized Version? Request It Now: A Dynamic Competitive Landscape and International Opportunities The competitive field is intensifying with a mix of established and new players. An August 2025 report identified 11 key players in the U.S. market, including Cannadips, VELO CBD, and FlowBlend. A separate August 2024 report profiled 10 major players, among them METOLIUS HEMP COMPANY and Canndid. The launch of new companies like Juana Dips in 2024 indicates a healthy and growing ecosystem. This competition is unfolding on a global stage with distinct international rules. For instance, following 2024 legal changes, adults in Malta can possess 7 grams of cannabis and cultivate 4 plants, though public consumption carries a 500 Euro fine. As of April 2024, Switzerland has an updated enforcement aid for CBD, and product approvals for the entire bloc of 27 EU member states are under review, creating a complex but opportunity-rich international CBD pouches market. Global CBD Pouches Market Major Players: Comp9 Canndid Chillbar FlowBlend Cannadips Vibe CBD+CBG Jake's Mint Chew Nicopods ehf. V&YOU Metolius Hemp Company Key Market Segmentation: By Type Flavored Unflavored By Content Up to 10 mg 10 mg-20 mg Others By Distribution Channel Online Offline By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
